CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) and uniQure (NASDAQ:QURE – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.
Valuation and Earnings
This table compares CollPlant Biotechnologies and uniQure”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CollPlant Biotechnologies | $318,000.00 | 21.62 | -$11.49 million | ($13.59) | -0.27 |
| uniQure | $18.67 million | 85.95 | -$198.97 million | ($4.01) | -5.77 |
CollPlant Biotechnologies has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares CollPlant Biotechnologies and uniQure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CollPlant Biotechnologies | -678.37% | -298.21% | -167.83% |
| uniQure | -1,350.73% | -111.96% | -29.01% |
Insider and Institutional Ownership
21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
CollPlant Biotechnologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, uniQure has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and target prices for CollPlant Biotechnologies and uniQure, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CollPlant Biotechnologies | 1 | 1 | 0 | 0 | 1.50 |
| uniQure | 1 | 3 | 12 | 1 | 2.76 |
CollPlant Biotechnologies presently has a consensus price target of $120.00, suggesting a potential upside of 3,201.24%. uniQure has a consensus price target of $53.25, suggesting a potential upside of 130.17%. Given CollPlant Biotechnologies’ higher possible upside, research analysts plainly believe CollPlant Biotechnologies is more favorable than uniQure.
Summary
uniQure beats CollPlant Biotechnologies on 9 of the 15 factors compared between the two stocks.
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
